Palisade Bio, Inc. Common Stock
PALIStock
$1.89+170.67%52W
Market Cap$351.50M
P/E—
Div yield—
Beta1.46
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-8.96%
Price vs S&P 500 (4W)13.45%
VGM Score45.56
Market Capitalization$351.50M
Earnings Surprise History
Q1 26-0.05est. -0.04
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.21
4.21
4.21
4.27
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PALIPalisade Bio, Inc. Common Stock | D | — | B | $1.89 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Palisade Bio is a clinical-stage biopharmaceutical company developing therapeutics to protect intestinal barrier function. Its lead candidate, PALI-2108, targets inflammatory bowel disease, including ulcerative colitis and Crohn's disease, while PALI-1908 is in early-stage research. The company is positioned in the gastrointestinal immunology market.